Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bexxar tositumomab: NDA under review

Long-term follow-up from five trials showed 76 of 250 patients (30.4%) on Bexxar achieved

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE